Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.Bull World Health Organ. 1985; 63(3):513-9.BW
Abstract
The preliminary results of a study of the incidence of breast cancer in relation to use of depot-medroxyprogesterone acetate (DMPA) are presented. The findings are based on data from three participating centres in Thailand, and one each in Kenya and Mexico. A relative risk for breast cancer of 0.7 was observed in women who had ever used DMPA; this was not statistically significant. Although no consistent decrease in risk with duration of use was observed, the lowest relative risk (0.5) was observed in women who had used DMPA for three or more years. These findings are based on small numbers and must be considered preliminary. However, they provide no evidence that DMPA increases the risk of breast cancer, and suggest that it may exert a protective effect, particularly in long-term users.
Links
MeSH
Pub Type(s)
Comparative Study
Journal Article
Language
eng
PubMed ID
2931206
Citation
Thomas, D B., et al. "Breast Cancer and Depot-medroxyprogesterone Acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives." Bulletin of the World Health Organization, vol. 63, no. 3, 1985, pp. 513-9.
Thomas DB, Noonan L, Whitehead A. Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Bull World Health Organ. 1985;63(3):513-9.
Thomas, D. B., Noonan, L., & Whitehead, A. (1985). Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Bulletin of the World Health Organization, 63(3), 513-9.
Thomas DB, Noonan L, Whitehead A. Breast Cancer and Depot-medroxyprogesterone Acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Bull World Health Organ. 1985;63(3):513-9. PubMed PMID: 2931206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Breast cancer and depot-medroxyprogesterone acetate. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
AU - Thomas,D B,
AU - Noonan,L,
AU - Whitehead,A,
PY - 1985/1/1/pubmed
PY - 1985/1/1/medline
PY - 1985/1/1/entrez
KW - Africa
KW - Africa South Of The Sahara
KW - Americas
KW - Asia
KW - Breast Cancer
KW - Cancer
KW - Central America
KW - Contraception
KW - Contraceptive Agents, Female--side effects
KW - Contraceptive Agents, Progestin--side effects
KW - Contraceptive Agents--side effects
KW - Depo-provera--side effects
KW - Developed Countries
KW - Developing Countries
KW - Diseases
KW - Eastern Africa
KW - English Speaking Africa
KW - Family Planning
KW - Incidence
KW - Kenya
KW - Latin America
KW - Measurement
KW - Medroxyprogesterone Acetate--side effects
KW - Mexico
KW - Neoplasms
KW - North America
KW - Research Methodology
KW - Southeastern Asia
KW - Thailand
SP - 513
EP - 9
JF - Bulletin of the World Health Organization
JO - Bull World Health Organ
VL - 63
IS - 3
N2 - The preliminary results of a study of the incidence of breast cancer in relation to use of depot-medroxyprogesterone acetate (DMPA) are presented. The findings are based on data from three participating centres in Thailand, and one each in Kenya and Mexico. A relative risk for breast cancer of 0.7 was observed in women who had ever used DMPA; this was not statistically significant. Although no consistent decrease in risk with duration of use was observed, the lowest relative risk (0.5) was observed in women who had used DMPA for three or more years. These findings are based on small numbers and must be considered preliminary. However, they provide no evidence that DMPA increases the risk of breast cancer, and suggest that it may exert a protective effect, particularly in long-term users.
SN - 0042-9686
UR - https://www.unboundmedicine.com/medline/citation/2931206/Breast_cancer_and_depot_medroxyprogesterone_acetate__WHO_Collaborative_Study_of_Neoplasia_and_Steroid_Contraceptives_
DB - PRIME
DP - Unbound Medicine
ER -
